Literature DB >> 15312672

Stability improvement of antibodies for extracellular and intracellular applications: CDR grafting to stable frameworks and structure-based framework engineering.

Stefan Ewert1, Annemarie Honegger, Andreas Plückthun.   

Abstract

By combining the knowledge gained from an analysis of the biophysical properties of natural antibody variable domains, the effects of mutations obtained in directed evolution experiments, and the detailed structural comparison of antibodies, it has now become possible to engineer antibodies for higher thermodynamic stability and more efficient folding. This is particularly important when antibodies are to be used under conditions where the disulfide bonds cannot form, i.e., in intracellular applications (as "intrabodies"). We describe in detail two methods for the knowledge-based improvement of antibody stability and folding efficiency. While CDR grafting from a non-human to the most closely related human antibody framework is an established technique to reduce the immunogenicity of a therapeutic antibody, CDR grafting for stabilization implies the use of a more distantly related acceptor framework with superior biophysical characteristics. The use of such dissimilar frameworks requires particular attention to antigen contact residues outside the classical CDR definition and to residues capable of indirectly affecting the conformation of the antigen binding site. As a second alternative, the stability of a suboptimal framework can be improved by the introduction of point mutations designed to optimize key residue interactions. We describe the analysis methods used to identify such point mutations, which can be introduced all at once, while maintaining the framework features necessary for antigen binding. These rational approaches render the continued "rediscovery" of certain mutations by directed evolution unnecessary, but they can also be used in conjunction with such methods to discover even better molecules.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15312672     DOI: 10.1016/j.ymeth.2004.04.007

Source DB:  PubMed          Journal:  Methods        ISSN: 1046-2023            Impact factor:   3.608


  68 in total

Review 1.  Molecular engineering of antibodies for therapeutic and diagnostic purposes.

Authors:  Frédéric Ducancel; Bruno H Muller
Journal:  MAbs       Date:  2012-07-01       Impact factor: 5.857

2.  Relative stabilities of IgG1 and IgG4 Fab domains: influence of the light-heavy interchain disulfide bond architecture.

Authors:  James T Heads; Ralph Adams; Lena E D'Hooghe; Matt J T Page; David P Humphreys; Andrew G Popplewell; Alastair D Lawson; Alistair J Henry
Journal:  Protein Sci       Date:  2012-08-09       Impact factor: 6.725

3.  Directed evolution methods for overcoming trade-offs between protein activity and stability.

Authors:  Samuel D Stimple; Matthew D Smith; Peter M Tessier
Journal:  AIChE J       Date:  2019-10-09       Impact factor: 3.993

Review 4.  Advances in Antibody Design.

Authors:  Kathryn E Tiller; Peter M Tessier
Journal:  Annu Rev Biomed Eng       Date:  2015-08-14       Impact factor: 9.590

5.  Design and Generation of Humanized Single-chain Fv Derived from Mouse Hybridoma for Potential Targeting Application.

Authors:  Kannika Khantasup; Warangkana Chantima; Chak Sangma; Kanokwan Poomputsa; Tararaj Dharakul
Journal:  Monoclon Antib Immunodiagn Immunother       Date:  2015-12

6.  Critical contribution of VH-VL interaction to reshaping of an antibody: the case of humanization of anti-lysozyme antibody, HyHEL-10.

Authors:  Takeshi Nakanishi; Kouhei Tsumoto; Akiko Yokota; Hidemasa Kondo; Izumi Kumagai
Journal:  Protein Sci       Date:  2008-02       Impact factor: 6.725

7.  Generic approach for the generation of stable humanized single-chain Fv fragments from rabbit monoclonal antibodies.

Authors:  Leo Borras; Tea Gunde; Julia Tietz; Ulrich Bauer; Valérie Hulmann-Cottier; John P A Grimshaw; David M Urech
Journal:  J Biol Chem       Date:  2010-01-07       Impact factor: 5.157

8.  Affinity maturation of antibodies assisted by in silico modeling.

Authors:  Rodrigo Barderas; Johan Desmet; Peter Timmerman; Rob Meloen; J Ignacio Casal
Journal:  Proc Natl Acad Sci U S A       Date:  2008-06-23       Impact factor: 11.205

9.  An anti-hapten camelid antibody reveals a cryptic binding site with significant energetic contributions from a nonhypervariable loop.

Authors:  Sean W Fanning; James R Horn
Journal:  Protein Sci       Date:  2011-05-23       Impact factor: 6.725

10.  Defining the complementarities between antibodies and haptens to refine our understanding and aid the prediction of a successful binding interaction.

Authors:  Mohammed M Al Qaraghuli; Soumya Palliyil; Gillian Broadbent; David C Cullen; Keith A Charlton; Andrew J Porter
Journal:  BMC Biotechnol       Date:  2015-10-24       Impact factor: 2.563

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.